GR1005424B - Method for quantitative determination of ck19 expression - Google Patents

Method for quantitative determination of ck19 expression

Info

Publication number
GR1005424B
GR1005424B GR20050100430A GR20050100430A GR1005424B GR 1005424 B GR1005424 B GR 1005424B GR 20050100430 A GR20050100430 A GR 20050100430A GR 20050100430 A GR20050100430 A GR 20050100430A GR 1005424 B GR1005424 B GR 1005424B
Authority
GR
Greece
Prior art keywords
quantitative determination
expression
positive cells
biological samples
relates
Prior art date
Application number
GR20050100430A
Other languages
Greek (el)
Inventor
Βασιλης Γεωργουλιας
Δημητριος Μαυρουδης
Ευρυκλεια Λιανιδου
Αλικη Σταθοπουλου
Original Assignee
Medexis Αεβε
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medexis Αεβε filed Critical Medexis Αεβε
Priority to GR20050100430A priority Critical patent/GR1005424B/en
Priority to EP06776902.6A priority patent/EP1915461B1/en
Priority to CA002617693A priority patent/CA2617693A1/en
Priority to AU2006281569A priority patent/AU2006281569A1/en
Priority to US11/990,575 priority patent/US20100015604A1/en
Priority to JP2008526444A priority patent/JP2009504168A/en
Priority to KR1020087006461A priority patent/KR20080036646A/en
Priority to CN200680037658.3A priority patent/CN101365800B/en
Priority to PCT/EP2006/008097 priority patent/WO2007020081A1/en
Publication of GR1005424B publication Critical patent/GR1005424B/en
Priority to US14/031,051 priority patent/US9593374B2/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method for quantitative determination of CK-19 mRNA positive cells in biological samples. In particular the invention relates to a method for quantitative determination of CK-19 mRNA positive cells in biological samples of patients suffering from cancer before the initiation of any adjuvant treatment in order to provide information concerning the effectiveness of the adjuvant therapy.
GR20050100430A 2005-08-17 2005-08-17 Method for quantitative determination of ck19 expression GR1005424B (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GR20050100430A GR1005424B (en) 2005-08-17 2005-08-17 Method for quantitative determination of ck19 expression
EP06776902.6A EP1915461B1 (en) 2005-08-17 2006-08-16 Composition and method for determination of ck19 expression
CA002617693A CA2617693A1 (en) 2005-08-17 2006-08-16 Composition and method for determination of ck19 expression
AU2006281569A AU2006281569A1 (en) 2005-08-17 2006-08-16 Composition and method for determination of CK19 expression
US11/990,575 US20100015604A1 (en) 2005-08-17 2006-08-16 Composition and method for determination of ck19 expression
JP2008526444A JP2009504168A (en) 2005-08-17 2006-08-16 Composition and method for confirming CK19 expression
KR1020087006461A KR20080036646A (en) 2005-08-17 2006-08-16 Compositions and Methods for Measuring CB1 Expression
CN200680037658.3A CN101365800B (en) 2005-08-17 2006-08-16 Compositions and methods for determining expression of CK19
PCT/EP2006/008097 WO2007020081A1 (en) 2005-08-17 2006-08-16 Composition and method for determination of ck19 expression
US14/031,051 US9593374B2 (en) 2005-08-17 2013-09-19 Composition and method for determination of CK19 expression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20050100430A GR1005424B (en) 2005-08-17 2005-08-17 Method for quantitative determination of ck19 expression

Publications (1)

Publication Number Publication Date
GR1005424B true GR1005424B (en) 2007-02-01

Family

ID=38121845

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20050100430A GR1005424B (en) 2005-08-17 2005-08-17 Method for quantitative determination of ck19 expression

Country Status (2)

Country Link
CN (1) CN101365800B (en)
GR (1) GR1005424B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102565404B (en) * 2010-12-24 2014-04-16 牛刚 Kit for detecting free colorectal cancer cell markers in blood
CN102109525B (en) * 2011-01-26 2013-10-16 牛刚 Kit for detecting free breast cancer cell marker in blood
CN103122387B (en) * 2013-02-05 2015-02-04 苏州华益美生物科技有限公司 Rapid circulating tumor cell (CTCs) fluorescence PCR (Polymerase Chain Reaction) hypersensitivity detection kit and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097878A1 (en) * 2002-05-21 2003-11-27 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
CA2553303C (en) * 2004-01-14 2014-06-10 Novahep Ab Human hepatic progenitor cells and methods of use thereof

Also Published As

Publication number Publication date
CN101365800B (en) 2014-07-02
CN101365800A (en) 2009-02-11

Similar Documents

Publication Publication Date Title
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
Mahmoud et al. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
BRPI0511139A (en) compounds, pharmaceutical composition comprising them, method for inhibiting aurora kinase activity in a cell and method for treating an aurora kinase mediated disorder in a patient
MX2012004258A (en) Inhibitors of bruton's tyrosine kinase.
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
MX2022009759A (en) Diarylhydantoin compounds.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
ZA200803517B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ZA200803430B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
ZA200804509B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ZA200803516B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
WO2009074968A3 (en) Method for predicting the efficacy of cancer therapy
WO2008106175A3 (en) Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors
MX2009005941A (en) Companion diagnostic assays for cancer therapy.
IL182813A0 (en) Methods and systems for prognosis and treatment of solid tumors
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
MY147634A (en) New crystalline forms
WO2008089135A3 (en) Identification of biomarkers predictive of dasatinib effects in cancer cells
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment

Legal Events

Date Code Title Description
PG Patent granted
ML Lapse due to non-payment of fees

Effective date: 20120302